This year has seen a number of tech giants like Snap, Cloudera, and Roku, make the jump into public markets. Meanwhile, one lesser-known company, Alteryx, which made its IPO in March, is quietly raking in the gains. Dean Stoecker, CEO of Alteryx, an analytics platform for enterprises, joined Cheddar to explain what’s clicking for his company.
The company's stock is up significantly from its IPO price of $14 a share. Stoecker explains how Alteryx's uncoventional path to IPO set the analytics company up for a strong start. He says raising money is a weakness, not a strength. That's why it took him 14 years to take in investments, and 20 years to move into the public spotlight.
Stoecker says Alteryx is bringing the thrill back to analytics. The company has a giant list of customers, including Walmart and Boeing. The CEO breaks down how Alteryx is looking to change the way these companies interpret data.
Seth Schachner, Managing Director at Strat Americas, on Hollywood's latest blockbusters utilizing content creation. Plus, the future of YouTube and TikTok.
Ashley Gold, Axios' Tech/Policy reporter, discusses what the future of Google and search engines will look like after the tech giant faces an antitrust trial.
A labor rights group has alleged that Starbucks sourced coffee from a major Brazilian cooperative whose member farms were cited for keeping workers in slave-like conditions.
X, the social media platform owned by Trump adviser Elon Musk, is challenging the constitutionality of a Minnesota ban on using deepfakes to influence elections and harm candidates.
Seth Goldstein, Equity Strategist at Morningstar, breaks down Tesla's earnings report, talks Musk's future with the company and how stocks have responded.
Senior Health Correspondent for TIME, Alice Park, gives us a deeper look into how Eli Lilly's new pill orforglipron may change the healthcare industry.
